Biote is a woman-led company operating a high growth, differentiated medical practice-building business within the hormone optimization space. Similar to a franchise model, Biote provides the necessary components to enable practitioners to establish, build, and successfully operate a hormone optimization center to treat patients appropriate for therapy. Biote trains practitioners how to identify and treat early indicators of hormone-related aging conditions.
![biote Corp - Ordinary Shares logo](/files/LOGO/1819253-BTMD.png)
Company profile
Ticker
BTMD
Exchange
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
Haymaker Acquisition Corp. III
SEC CIK
BTMD stock data
Latest filings (excl ownership)
8-K
Entry into a Material Definitive Agreement
5 Jul 24
8-K
Departure of Directors or Certain Officers
3 Jul 24
8-K
Biote Announces $60 Million Agreement to Repurchase 8.3 Million Shares and Cancel Approximately 4.0 Million Earnout Shares
20 Jun 24
8-K
Submission of Matters to a Vote of Security Holders
24 May 24
424B3
Prospectus supplement
10 May 24
424B3
Prospectus supplement
10 May 24
10-Q
2024 Q1
Quarterly report
10 May 24
8-K
Biote Reports First Quarter 2024 Financial Results
7 May 24
8-K
Biote Announces Definitive Settlement with Founder
29 Apr 24
ARS
2023 FY
Annual report to shareholders
11 Apr 24
Latest ownership filings
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 78.79 mm | 78.79 mm | 78.79 mm | 78.79 mm | 78.79 mm | 78.79 mm |
Cash burn (monthly) | 3.41 mm | (no burn) | (no burn) | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | 13.17 mm | n/a | n/a | n/a | n/a | n/a |
Cash remaining | 65.62 mm | n/a | n/a | n/a | n/a | n/a |
Runway (months of cash) | 19.3 | n/a | n/a | n/a | n/a | n/a |
Institutional ownership, Q1 2024
13.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 11 |
Opened positions | 9 |
Closed positions | 2 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 5.01 bn |
Total shares | 3.93 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Roystone Capital Management | 3.07 mm | $17.01 mm |
Wasatch Advisors | 669.86 k | $3.89 bn |
Skylands Capital | 118.12 k | $685.07 mm |
BK Bank Of New York Mellon | 59.32 k | $344.05 mm |
ZWJ Investment Counsel | 12.75 k | $73.93 mm |
Global Retirement Partners | 500.00 | $2.90 mm |
Amalgamated Bank. | 472.00 | $3.00 k |
Nelson, Van Denburg & Campbell Wealth Management | 448.00 | $2.60 mm |
Nisa Investment Advisors | 67.00 | $389.00 k |
GAMMA Investing | 41.00 | $238.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
9 Jul 24 | Robert Charles Peterson | Class A Common Stock | Sell | Dispose S | No | No | 7.5672 | 11,376 | 86.08 k | 32,874 |
8 Jul 24 | Robert Charles Peterson | Class A Common Stock | Option exercise | Acquire M | No | No | 0 | 44,250 | 0.00 | 44,250 |
8 Jul 24 | Robert Charles Peterson | RSU Class A Common Stock | Option exercise | Dispose M | No | No | 0 | 44,250 | 0.00 | 0 |
21 May 24 | Stephen Mark Cone | Stock Option Class A Common Stock | Grant | Acquire A | No | No | 5.57 | 65,258 | 363.49 k | 143,763 |
21 May 24 | Stephen Mark Cone | Deferred Settlement RSU Class A Common Stock | Grant | Acquire A | No | No | 0 | 10,828 | 0.00 | 20,352 |
21 May 24 | Heyer Andrew R | Stock Option Class A Common Stock | Grant | Acquire A | No | No | 5.57 | 65,258 | 363.49 k | 175,459 |
21 May 24 | Heyer Andrew R | Deferred Settlement RSU Class A Common Stock | Grant | Acquire A | No | No | 0 | 13,427 | 0.00 | 25,436 |
21 May 24 | Debra L Morris | Class A Common Stock | Option exercise | Acquire M | No | No | 0 | 9,110 | 0.00 | 39,110 |
21 May 24 | Debra L Morris | Stock Option Class A Common Stock | Grant | Acquire A | No | No | 5.57 | 65,258 | 363.49 k | 153,657 |
21 May 24 | Debra L Morris | Deferred Settlement RSU Class A Common Stock | Grant | Acquire A | No | No | 0 | 10,395 | 0.00 | 10,395 |
News
Watching Biote; Shares Spike Lower As J Capital Issues Report On Company, Announcing It Has Taken A Short Position
20 May 24
Biote Reiterates Guidance
7 May 24
Biote Q1 2024 GAAP EPS $(0.06) Misses $0.03 Estimate, Sales $46.804M Beat $45.711M Estimate
7 May 24
Biote Announces Definitive Settlement With Founder, Company To Repurchase All Of Founder's 18.4M Shares At $4.17 Per Share
29 Apr 24